Earnings Feed
Start Free
AGIOS PHARMACEUTICALS, INC.·4

Jun 23, 5:25 PM ET

Ballal Rahul D. 4

Research Summary

AI-generated summary

Updated

AGIOS (AGIO) Director Rahul D. Ballal Receives RSUs, Exercises Derivatives

What Happened

  • Rahul D. Ballal, a director of Agios Pharmaceuticals (AGIO), had derivative securities converted and received new equity awards on June 18, 2026. The filing shows:
    • Conversion/exercise of 2,816 derivative units into 2,816 shares (transaction code M) at $0.00; an equal number (2,816) were concurrently recorded as disposed at $0.00.
    • Grants/awards recorded as acquisitions of 2,927 and 14,950 derivative units (transaction code A) at $0.00.
  • No cash changed hands in the listed transactions (all prices reported as $0.00).

Key Details

  • Transaction date: June 18, 2026; Form 4 filed June 23, 2026.
  • Prices: all entries listed at $0.00 (conversion/vesting or net settlement rather than an open‑market purchase).
  • Shares acquired/awarded: 2,927 RSU units and 14,950 derivative units (total 17,877 new units granted); 2,816 units converted/exercised with an equal 2,816 disposed.
  • Shares owned after the transactions: not specified in the filing.
  • Footnotes:
    • F1: Each restricted stock unit (RSU) converts to one share when vested.
    • F2: The 2,927 RSUs were granted 6/18/2025 and vest in full 6/18/2026; vested shares delivered within three business days after vesting.
    • F3: The 14,950 RSUs were granted 6/18/2026 and vest in full 6/18/2027.
    • F4: Options noted were granted 6/18/2026 and vest 100% on 6/18/2027.
  • Timeliness: the Form 4 was filed five days after the June 18 transactions. Form 4s are generally due within two business days, so this filing appears later than the typical deadline.

Context

  • The M (exercise/conversion) entries and matching zero-dollar disposed entry commonly reflect conversion/vesting events with shares withheld or net‑settled to satisfy tax or other obligations rather than an open‑market sale. The filing indicates grants and vesting activity rather than a cash purchase or a deliberate market sale by the director.
  • These transactions are routine equity compensation events for insiders; they are informative about compensation and future potential dilution but do not necessarily signal a change in the director’s view of the company.